KR100292995B1 - 단백질분해효소억제제인사카린유도체 - Google Patents

단백질분해효소억제제인사카린유도체 Download PDF

Info

Publication number
KR100292995B1
KR100292995B1 KR1019920024707A KR920024707A KR100292995B1 KR 100292995 B1 KR100292995 B1 KR 100292995B1 KR 1019920024707 A KR1019920024707 A KR 1019920024707A KR 920024707 A KR920024707 A KR 920024707A KR 100292995 B1 KR100292995 B1 KR 100292995B1
Authority
KR
South Korea
Prior art keywords
alkyl
alkoxy
phenyl
alkylamino
piperazinyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1019920024707A
Other languages
English (en)
Korean (ko)
Inventor
데니스존라스타
제임스호워드액커만
알버트조셉뮤라
Original Assignee
디. 꼬쉬
사노피
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 디. 꼬쉬, 사노피 filed Critical 디. 꼬쉬
Application granted granted Critical
Publication of KR100292995B1 publication Critical patent/KR100292995B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
    • C07D275/04—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D275/06—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems with hetero atoms directly attached to the ring sulfur atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Cosmetics (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyrrole Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Bakery Products And Manufacturing Methods Therefor (AREA)
  • Beans For Foods Or Fodder (AREA)
  • Fertilizers (AREA)
  • Medicinal Preparation (AREA)
KR1019920024707A 1991-12-19 1992-12-17 단백질분해효소억제제인사카린유도체 Expired - Fee Related KR100292995B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US81026591A 1991-12-19 1991-12-19
US810,265 1991-12-19

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020000061842A Division KR100378968B1 (ko) 1991-12-19 2000-10-20 단백질 분해 효소 억제제인 사카린 유도체를 포함하는약학 조성물

Publications (1)

Publication Number Publication Date
KR100292995B1 true KR100292995B1 (ko) 2001-09-17

Family

ID=25203432

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1019920024707A Expired - Fee Related KR100292995B1 (ko) 1991-12-19 1992-12-17 단백질분해효소억제제인사카린유도체
KR1020000061842A Expired - Fee Related KR100378968B1 (ko) 1991-12-19 2000-10-20 단백질 분해 효소 억제제인 사카린 유도체를 포함하는약학 조성물

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020000061842A Expired - Fee Related KR100378968B1 (ko) 1991-12-19 2000-10-20 단백질 분해 효소 억제제인 사카린 유도체를 포함하는약학 조성물

Country Status (19)

Country Link
EP (1) EP0547708B1 (cg-RX-API-DMAC10.html)
JP (1) JP3179600B2 (cg-RX-API-DMAC10.html)
KR (2) KR100292995B1 (cg-RX-API-DMAC10.html)
AT (1) ATE233250T1 (cg-RX-API-DMAC10.html)
AU (1) AU668694B2 (cg-RX-API-DMAC10.html)
CA (1) CA2084857A1 (cg-RX-API-DMAC10.html)
CZ (1) CZ283257B6 (cg-RX-API-DMAC10.html)
DE (1) DE69232929D1 (cg-RX-API-DMAC10.html)
FI (1) FI925787A7 (cg-RX-API-DMAC10.html)
HU (1) HU219950B (cg-RX-API-DMAC10.html)
IL (1) IL104154A (cg-RX-API-DMAC10.html)
MX (1) MX9207449A (cg-RX-API-DMAC10.html)
MY (1) MY110104A (cg-RX-API-DMAC10.html)
NO (1) NO300770B1 (cg-RX-API-DMAC10.html)
NZ (1) NZ245518A (cg-RX-API-DMAC10.html)
RU (1) RU2107685C1 (cg-RX-API-DMAC10.html)
SG (1) SG52659A1 (cg-RX-API-DMAC10.html)
SK (1) SK374692A3 (cg-RX-API-DMAC10.html)
TW (1) TW225532B (cg-RX-API-DMAC10.html)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5378720A (en) * 1991-12-19 1995-01-03 Sterling Winthrop Inc. Saccharin derivative proteolytic enzyme inhibitors
US5541168A (en) * 1994-12-02 1996-07-30 Sterling Winthrop Inc. Substituted 2-(phosphinyloxymethyl)-1,2,5-thiadiazolidin-3-one 1,1-dioxides and compositions and method of use thereof
US5512576A (en) * 1994-12-02 1996-04-30 Sterling Winthrop Inc. 2-substituted 1,2,5,-thiadiazolidin-3-one 1,1-dioxides and compositions and method of use thereof
DE19533643A1 (de) * 1995-09-12 1997-03-13 Nycomed Arzneimittel Gmbh Neue cyclische Derivate von Benzolsulfonamiden
US5750550A (en) * 1995-09-15 1998-05-12 Sanofi 2-(pyrazol-5-yl-oxymethyl)-1,2-benzisothiazol-3 (2H)-One 1, 1-dioxides and compositions and method of use thereof
US7482366B2 (en) 2001-12-21 2009-01-27 X-Ceptor Therapeutics, Inc. Modulators of LXR
US7998986B2 (en) 2001-12-21 2011-08-16 Exelixis Patent Company Llc Modulators of LXR
JP4164031B2 (ja) 2002-02-14 2008-10-08 ファルマシア コーポレーション Ｐ３８ｍａｐキナーゼのモジュレータとしての置換されたピリジノン
AR059898A1 (es) 2006-03-15 2008-05-07 Janssen Pharmaceutica Nv Derivados de 3-ciano-piridona 1,4-disustituida y su uso como moduladores alostericos de los receptores mglur2
NZ575685A (en) * 2006-10-04 2012-04-27 Bionomics Ltd Novel benzofuran potassium channel blockers and uses thereof
WO2008076427A2 (en) 2006-12-18 2008-06-26 Amgen Inc. Naphthalenone compounds exhibiting prolyl hydroxylase inhibitory activity, compositions, and uses thereof
US8048892B2 (en) 2006-12-18 2011-11-01 Amgen Inc. Azaquinolone based compounds exhibiting prolyl hydroxylase inhibitory activity, compositions, and uses thereof
TW200845978A (en) 2007-03-07 2008-12-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
TW200900065A (en) 2007-03-07 2009-01-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives
US7569726B2 (en) 2007-04-18 2009-08-04 Amgen Inc. Indanone derivatives that inhibit prolyl hydroxylase
ES2442847T3 (es) 2007-04-18 2014-02-13 Amgen, Inc Quinolonas y azaquinolonas que inhiben la prolil hidroxilasa
AU2008248165B2 (en) 2007-05-04 2011-12-08 Amgen Inc. Diazaquinolones that inhibit prolyl hydroxylase activity
EP2150251B9 (en) 2007-05-04 2013-02-27 Amgen, Inc Thienopyridine and thiazolopyridine derivatives that inhibit prolyl hydroxylase activity
CA2696948C (en) 2007-09-14 2013-04-30 Jose Maria Cid-Nunez 1',3'-disubstituted-4-phenyl-3,4,5,6-tetrahydro-2h,1'h-[1,4']bipyridinyl-2'-ones
CN102143955B (zh) 2008-09-02 2013-08-14 Omj制药公司 作为代谢型谷氨酸受体调节剂的3-氮杂二环[3.1.0]己烷衍生物
JP5690277B2 (ja) 2008-11-28 2015-03-25 ジャンセン ファーマシューティカルズ， インコーポレイテッド． 代謝型グルタミン酸受容体の調節因子としてのインドールおよびベンゾオキサジン誘導体
ES2440001T3 (es) 2009-05-12 2014-01-27 Janssen Pharmaceuticals, Inc. Derivados de 1,2,4-triazolo[4,3-A]piridina y su uso para el tratamiento o prevención de trastornos neurológicos y psiquiátricos
CN102439015B (zh) 2009-05-12 2015-05-13 杨森制药有限公司 1,2,4-三唑并[4,3-a]吡啶衍生物和其作为mGluR2受体的正向变构调节剂的用途
MY153913A (en) 2009-05-12 2015-04-15 Janssen Pharmaceuticals Inc 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
ES2552879T3 (es) 2010-11-08 2015-12-02 Janssen Pharmaceuticals, Inc. Derivados de 1,2,4-triazolo[4,3-a]piridina y su uso como moduladores alostéricos positivos de receptores mGluR2
CA2814998C (en) 2010-11-08 2019-10-29 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
US9271967B2 (en) 2010-11-08 2016-03-01 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors
JO3368B1 (ar) 2013-06-04 2019-03-13 Janssen Pharmaceutica Nv مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2
JO3367B1 (ar) 2013-09-06 2019-03-13 Janssen Pharmaceutica Nv مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2
LT3431106T (lt) 2014-01-21 2021-02-10 Janssen Pharmaceutica Nv Deriniai, apimantys 2 potipio metabotropinio glutamaterginio receptoriaus teigiamus alosterinius moduliatorius arba ortosterinius agonistus, ir jų panaudojimas
EA033889B1 (ru) 2014-01-21 2019-12-05 Янссен Фармацевтика Нв Комбинация на основе лиганда sv2a и положительного аллостерического модулятора метаботропного глутаматергического рецептора 2 подтипа

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4195023A (en) * 1975-08-20 1980-03-25 Merck & Co., Inc. 2-(2-Furoyl)1,2-benzisothiazole-3-one, 2-(2-furoyl) saccharin, and 2-(2-thenoyl) saccharin
US4276298A (en) * 1978-03-24 1981-06-30 Merck & Co., Inc. 2-Aryl-1,2-benzisothiazolinone-1,1-dioxides and their use as selective protease inhibitors
DE3617976A1 (de) * 1986-05-28 1988-01-14 Alter Sa 1,4-dihydropyridin, verfahren zu dessen herstellung und dessen verwendung in antithrombotischen medikamenten
DK0471756T3 (da) * 1989-05-04 1998-05-18 Sanofi Sa Saccharinderivater, der er egnede som proteolytiske enzyminhibitorer, og fremstilling deraf
AU642537B2 (en) * 1990-11-01 1993-10-21 Sanofi 2-saccharinylmethyl aryl carboxylates useful as proteolytic enzyme inhibitors and compositions and method of use thereof
AU656027B2 (en) * 1991-11-15 1995-01-19 Sanofi Saccharin derivative proteolytic enzime inhibitors

Also Published As

Publication number Publication date
NO924915L (no) 1993-06-21
NZ245518A (en) 1995-06-27
TW225532B (cg-RX-API-DMAC10.html) 1994-06-21
FI925787L (fi) 1993-06-20
MX9207449A (es) 1994-03-31
SK278390B6 (en) 1997-02-05
HUT67039A (en) 1995-01-30
FI925787A0 (fi) 1992-12-18
CZ374692A3 (en) 1993-08-11
IL104154A0 (en) 1993-05-13
FI925787A7 (fi) 1993-06-20
AU668694B2 (en) 1996-05-16
JP3179600B2 (ja) 2001-06-25
NO300770B1 (no) 1997-07-21
HU9204029D0 (en) 1993-04-28
AU2829292A (en) 1993-07-08
HU219950B (hu) 2001-09-28
JPH05345771A (ja) 1993-12-27
EP0547708A1 (en) 1993-06-23
SK374692A3 (en) 1997-02-05
EP0547708B1 (en) 2003-02-26
KR100378968B1 (ko) 2003-04-08
CA2084857A1 (en) 1993-06-20
NO924915D0 (no) 1992-12-18
DE69232929D1 (de) 2003-04-03
IL104154A (en) 1996-09-12
SG52659A1 (en) 1998-09-28
CZ283257B6 (cs) 1998-02-18
MY110104A (en) 1998-01-27
ATE233250T1 (de) 2003-03-15
RU2107685C1 (ru) 1998-03-27

Similar Documents

Publication Publication Date Title
KR100292995B1 (ko) 단백질분해효소억제제인사카린유도체
KR100334345B1 (ko) 단백질분해효소억제제인사카린유도체
KR900007780B1 (ko) 축합된 피롤리논 유도체의 제조방법
JP2793195B2 (ja) ベンゾチアゾール誘導体
EP0264586B1 (en) Hydantoin derivatives for treating complications of diabetes
CZ386992A3 (en) Novel 2-saccharinylmethylaryl- and aryloxyacetates usable as proteolytic enzymes inhibitors, said acetates composition and method of use
CZ386892A3 (en) Novel 2-saccharinylmethyl heterocyclic carboxylates usable as proteolytic enzymes inhibitors and their compositions and method of application
NO300373B1 (no) Analogifremgangsmåte for fremstilling av nye terapeutisk aktive 2-sakkarinylmetylarylkarboksylater
CA2007580A1 (en) Process for preparing a naphthalene derivative and a synthetic intermediate thereof
IL103747A (en) Saccharin derivatives and pharmaceutical compositions containing them
US4761425A (en) Leukotriene antagonists
CA1288107C (en) Leukotriene antagonists
US5773456A (en) Saccharin derivative proteolytic enzyme inhibitors
NZ228716A (en) Chromene derivatives and pharmaceutical compositions
HU211286A9 (hu) Proteolitikus enzimeket gátló szacharinszármazékok Az átmeneti oltalom az 1-5. és 8. igénypontokra vonatkozik.
JPH05247008A (ja) ナフトキノン誘導体
IL119685A (en) 4,5,6,7-tetrahydro-2-saccharinylmethyl aryl and aryloxy acetates
IL114773A (en) 2-Tetrahydro-saccharinylmethyl aryl carboxylates their preparation and pharmaceutical compositions containing them

Legal Events

Date Code Title Description
PA0109 Patent application

St.27 status event code: A-0-1-A10-A12-nap-PA0109

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

N231 Notification of change of applicant
PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

AMND Amendment
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

J201 Request for trial against refusal decision
PJ0201 Trial against decision of rejection

St.27 status event code: A-3-3-V10-V11-apl-PJ0201

A107 Divisional application of patent
PA0107 Divisional application

St.27 status event code: A-0-1-A10-A18-div-PA0107

St.27 status event code: A-0-1-A10-A16-div-PA0107

PB0901 Examination by re-examination before a trial

St.27 status event code: A-6-3-E10-E12-rex-PB0901

B701 Decision to grant
PB0701 Decision of registration after re-examination before a trial

St.27 status event code: A-3-4-F10-F13-rex-PB0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U11-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R11-asn-PN2301

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R14-asn-PN2301

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20040329

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20040329

P22-X000 Classification modified

St.27 status event code: A-4-4-P10-P22-nap-X000